Based on the 2024 Advisory Committee for Immunization Practices (ACIP) recommendations, which one of the following would be a recommended option for the hepatitis B vaccine and dosing schedule in a healthy adult who is nonimmune to hepatitis B virus (HBV)?
Figure 1. Heplisav-B Vaccine versus Engerix-B Vaccine in Healthy Adults 18-55 Years of Age
In this trial, the primary endpoint was the percentage of persons who achieved seroprotection 8 weeks after the final dose of the Heplisav-B vaccine series or 4 weeks after completing the Engerix-B vaccine series. Seroprotection was defined as an anti-HBs titer of at least 10 mIU/mL.
Source: Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine. 2012;30:2556-63.
Figure 2. Recommended Hepatitis B Vaccine Schedule in Adults
*Before a potential exposure, such as travel, Twinrix can be administered as an accelerated series on days 0, 7, 21-30, followed by a fourth dose at 12 months.
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
March 10th, 2025
March 10th, 2025
Steps to acquire a Certificate for this Lesson:
1
Answer Questions
Answer the board-review style questions
2
Answer Correctly
Score 80%+
3
Give Feedback
Complete survey
4
